Skip to content
Journal ArticleReviewJournal of diabetes and metabolic disorders·Graded and published ·Last edited

Semaglutide: About 12.7 kg More Weight Lost, More Dropouts

Graded Moderate — ten trials with 7,131 people chosen at random, but the authors rate the certainty of the evidence as low and results varied widely between trials.

Design
Meta-analysis
Participants
7,131
Duration
—
Funding
—
Key Insight

In trials, adults without diabetes lost about 12.7 kilograms more on semaglutide than on a dummy treatment.


Adults with obesity or overweight but no diabetes lost about 12.7 kilograms more on semaglutide than on a dummy treatment. Semaglutide belongs to the GLP-1 drugs and is approved for long-term weight management. But the weight loss came with more side effects. And the size of the benefit varied a lot from one trial to the next.

A research team pooled ten trials with 7,131 adults in total. In each, participants were chosen at random to get semaglutide or a dummy treatment. People could join with a BMI of 30 or more. A BMI of 27 or more was enough if they also had an illness linked to their weight. Waist size shrank by about 9 centimeters more. Side effects were more common: 6 percent stopped treatment because of them, compared with 3 percent on the dummy.

Whether serious side effects became more common remained unclear. The data showed no clear difference, but could not rule out an important increase. The authors themselves rate the certainty of the results as low. The figures also only cover the treatment period in the trials, not what happened afterwards.

Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.